Scarica l'app Stockscreener
23.56
2.88%
0.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$22.90
Aprire:
$23.04
Volume 24 ore:
1.35M
Relative Volume:
0.67
Capitalizzazione di mercato:
$3.99B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
130.89
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-1.92%
1M Prestazione:
+10.77%
6M Prestazione:
+7.83%
1 anno Prestazione:
+45.61%
Intervallo 1D:
$22.84
$23.98
Intervallo di 1 settimana:
$22.81
$24.50
Portata 52W:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.56 | 3.87B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
How ACADIA Pharmaceuticals Inc. stock trades before earningsInsider Buying & Real-Time Market Trend Scan - newser.com
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - BioSpace
Is ACADIA Pharmaceuticals Inc. stock oversold or undervalued2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 - openPR.com
Will ACADIA Pharmaceuticals Inc. stock split again soonShare Buyback & Verified Entry Point Detection - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Will ACADIA Pharmaceuticals Inc. stock attract more institutional investorsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
ACADIA Pharmaceuticals (ACAD): JP Morgan Lowers Price Target to $31.00 | ACAD Stock News - GuruFocus
Acadia Eyes Record-Breaking Revenue In 2025 With Nuplazid And Daybue - RTTNews
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights - MSN
(ACAD) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - Yahoo Finance
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - sharewise.com
Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals! - TipRanks
Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com - Investing.com Australia
Insider Sell: James Daly Sells 30,000 Shares of ACADIA Pharmaceu - GuruFocus
Acadia Pharmaceuticals director Daly sells $670k in stock - Investing.com
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersEarnings Summary Report & Daily Stock Momentum Reports - newser.com
Acadia Pharmaceuticals stock price target lowered by RBC on weak Medicaid volume - Investing.com Australia
What drives ACADIA Pharmaceuticals Inc stock priceVolatility Trading Techniques & Free Explosive Earning Power - earlytimes.in
Positive readouts validate pipelines, fuel drug developer rally - BioWorld MedTech
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):